A Review of Recent Advance Therapy of The MDR TB and DR TB
Year: 2025
Type: article
Abstract: TB still causes a significant amount of illness and mortality across the world, even after the low-cost and successful four-drug treatment regimen (isoniazid, rifampicin, pyrazinamide, and ethambutol) was introduced 40 years ago. For all types of tuberculosis, new and innovative medications and treatment plans are being developed for the first time since the 1960s. Both novel chemical entities and repurposed medications are anticipated to be used in such regimens, some of which are now advancing through clinical studies. Current ideas and recent developments in TB drug discovery and development are discussed in this article. These include an update on ongoing TB treatment studies, updated clinical trial designs, TB biomarkers, and adjunct host-directed medicines.
Author: Sushant Benade*, Fiza Patel, Priyanka Gavhade, Shradha Nerkar, Sheetal Rode, Dr. Ashok Giri
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6893218395
FWCI:
Cites:
Cited by:
Related to: